2013-12-02 13:20:01 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Vanda Pharmaceuticals Inc. (VNDA) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Vanda Pharmaceuticals Inc. (VNDA). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Vanda Pharmaceuticals Inc. investor.
Report Summary: Vanda Pharmaceuticals Inc. is an average quality company with a neutral outlook. Vanda Pharmaceuticals Inc. has strong business growth and is run by mediocre management. The trend in Vanda Pharmaceuticals Inc. fair value exchange rate against its closest rated-competitor, SurModics, Inc., has been appreciating over the past 2 weeks. When compared to its closest competitor, Vanda Pharmaceuticals Inc. shows similar overvaluation and is equally likely to outperform the market.
The report breaks down the Total StockMark into its three components
- business, management and price, performing an in-depth analysis of Vanda Pharmaceuticals Inc. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.